Tempest Therapeutics Adds Financial Veteran to Board Amid Growth Phase
Event summary
- Tempest Therapeutics appointed John W. Frederick to its board of directors on October 14, 2026.
- Frederick brings over three decades of experience in financial strategy, capital markets, and operational transformation.
- He previously served as CFO of Skillsoft and held leadership roles at Indigo Ag and Snagajob.
- Tempest is developing in vivo CAR-T therapies for cancer and autoimmune diseases.
The big picture
Tempest Therapeutics is strengthening its board with financial expertise as it navigates a critical phase of growth and capital deployment. The appointment of John W. Frederick, with his extensive background in financial strategy and capital markets, underscores the company's focus on disciplined capital allocation and long-term success. This move comes as Tempest advances its innovative in vivo CAR-T therapies, aiming to transform treatment for patients with significant unmet needs across multiple disease types.
What we're watching
- Capital Deployment
- How Frederick's expertise will influence Tempest's capital allocation strategy during its growth phase.
- Development Milestones
- Whether Tempest can achieve key milestones in its in vivo CAR-T programs with the new board member's guidance.
- Long-Term Growth
- The pace at which Tempest can build a strong foundation for sustainable growth and shareholder value.
Related topics
